ANNX stock forecast, quote, news & analysis
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye... Show more
Annexon (ANNX) Stock Analysis: Pipeline Momentum Builds
Key Takeaways
- Annexon submitted a Marketing Authorization Application for tanruprubart to the EMA for Guillain-Barré Syndrome, marking a key regulatory milestone.
- Phase 3 ARCHER II trial enrollment for vonaprument in geographic atrophy completed ahead of schedule, with topline data expected in the second half of 2026.
- Analysts maintain a Moderate Buy consensus with an average price target of $17, implying substantial upside from recent levels.
- 2026 positioned as pivotal year with multiple registrational milestones across neuroinflammatory disease programs.
- Stock has shown volatility but gained over 20% year-to-date amid positive pipeline updates.
Current Market Snapshot
Annexon (ANNX) stock has navigated volatility in recent trading sessions, reflecting investor focus on clinical progress in its complement-targeted immunotherapy platform. Shares have fluctuated within a broad 52-week range, supported by enthusiasm for late-stage assets addressing unmet needs in neuroinflammatory conditions like Guillain-Barré Syndrome and geographic atrophy. Trading volume has spiked around key announcements, underscoring sentiment tied to regulatory and trial advancements. The biotech remains pre-revenue, with market cap around $900 million, as attention centers on potential catalysts from ongoing Phase 3 programs and European regulatory reviews.
Recent Developments Driving ANNX Price Action
Annexon, a clinical-stage biopharmaceutical company developing C1q-targeted therapies for neuroinflammatory diseases, has seen its stock influenced by several pivotal updates in recent weeks. The most significant was the January 8, 2026, announcement of the Marketing Authorization Application (MAA) submission for tanruprubart (ANX005) to the European Medicines Agency (EMA) for Guillain-Barré Syndrome (GBS). This filing, supported by placebo-controlled and real-world evidence from the FORWARD trial, positions tanruprubart as a potential first targeted, fast-acting therapy for GBS, a serious autoimmune neuropathy. The news initially drove shares higher, highlighting the company's lead in complement inhibition for acute neuroinflammation, though subsequent pullbacks reflected typical biotech volatility amid U.S. FDA discussions for a planned 2026 Biologics License Application (BLA).
On January 12, 2026, Annexon outlined its accelerated immunotherapy platform, emphasizing multiple registrational milestones in 2026. This included completion of enrollment in the global Phase 3 ARCHER II trial for vonaprument (ANX007) in dry age-related macular degeneration (dAMD) with geographic atrophy (GA), ahead of schedule. Topline data from this 659-patient study, evaluating vision preservation via neuroprotective effects, is slated for the second half of 2026. Prior Phase 2 results showed dose-dependent reductions in vision loss, differentiating it in a competitive GA market dominated by broader complement inhibitors.
Earlier, on January 7, Annexon presented at the J.P. Morgan Healthcare Conference, reinforcing its "pivotal" 2026 outlook with ANX007 readout and ANX005 filings. Minor news like January 16 inducement grants had negligible impact. Analyst reactions bolstered sentiment: Chardan initiated Buy at $16, Cantor Fitzgerald reiterated Overweight, and consensus holds Moderate Buy with $14-17 targets from firms like Wells Fargo ($27). Positive news sentiment score of 1.68 exceeds biotech peers, driving search interest up 36% and watchlist adds 150%.
Price action linked directly to these catalysts: shares hit 52-week highs near $7 amid MAA buzz and trial updates, before recent consolidation around $5-6 amid broader market pressures on small-cap biotechs. No earnings in the period, but Q3 2025 results (EPS miss at -$0.37) were overshadowed by pipeline momentum. Macro factors like biotech sector rotation added pressure, yet fundamentals—cash into late 2027—support resilience.
2026 Outlook and Key Factors to Monitor
As Annexon advances its C1q platform, 2026 emerges as a transformative year with high-stakes milestones across ophthalmology, autoimmunity, and neurodegeneration. Investors should track topline results from the Phase 3 ARCHER II trial of vonaprument in GA secondary to dAMD, expected in H2 2026, which could validate its unique vision-preserving profile amid competition from approved therapies like those targeting C3 or C5. Progress on tanruprubart's EMA review and planned U.S. BLA submission, leveraging FORWARD trial data, will be critical for GBS market entry potential.
Early proof-of-concept for oral C1q inhibitor ANX1502 in cold agglutinin disease, with updates anticipated, could expand the pipeline into broader autoimmune indications. Regulatory feedback from EMA and FDA, trial execution risks, and partnership opportunities in large markets like GA (millions affected globally) remain focal points. Competitive dynamics in complement inhibition, manufacturing scale-up, and cash burn through late 2027 will influence trajectory. Balanced against these are opportunities in underserved neuroinflammatory spaces, where Annexon's targeted approach may offer differentiated efficacy.
ANNX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ANNX turned positive on May 27, 2026. Looking at past instances where ANNX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANNX's RSI Oscillator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 29, 2026. You may want to consider a long position or call options on ANNX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANNX advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where ANNX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
ANNX moved below its 50-day moving average on May 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANNX crossed bearishly below the 50-day moving average on May 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ANNX entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.209) is normal, around the industry mean (21.430). P/E Ratio (0.000) is within average values for comparable stocks, (35.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). ANNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (362.782).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain
Industry Biotechnology